This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Xenon Named Life Sciences Company Of The Year By LifeSciences British Columbia

VANCOUVER, Canada, April 8, 2013 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded the LifeSciences British Columbia Life Sciences Company of the Year Award for 2013. 


The LifeSciences British Columbia Awards took take place on Thursday, April 4 at the Vancouver Convention Centre with several hundred guests representing the British Columbia life sciences community. 

"We are honored to be recognized by our industry peers in this way," commented Simon Pimstone, Xenon's President and CEO.  "This is the beginning of a very exciting year for Xenon.  We've worked diligently and deliberately to create strong partnerships with top tier pharmaceutical companies and to develop a deep and diverse pipeline of products.  One of Xenon's early technologies is now in an approved product to treat lipoprotein lipase deficiency, we have a late stage clinical program initiating for our novel pain medicine and an early development stage product for the treatment of anemia.  We look forward to an exciting year at Xenon as our products advance on the market and in the clinic." 

About Xenon Pharmaceuticals Inc. Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel therapies for rare diseases. For more information, visit the Company's website at

For more information regarding this press release, contact: Dr. Robin Sherrington, SVP Business & Corporate Development  (604) 484-3300,

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SOURCE Xenon Pharmaceuticals Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs